<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Momenilandi M</submitter><funding>NIDCR NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>European Research Council</funding><funding>Howard Hughes Medical Institute</funding><funding>NIAID NIH HHS</funding><funding>LEO Foundation</funding><funding>NCI NIH HHS</funding><pagination>2817-2837.e31</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11149630</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>187(11)</volume><pubmed_abstract>FMS-related tyrosine kinase 3 ligand (FLT3L), encoded by FLT3LG, is a hematopoietic factor essential for the development of natural killer (NK) cells, B cells, and dendritic cells (DCs) in mice. We describe three humans homozygous for a loss-of-function FLT3LG variant with a history of various recurrent infections, including severe cutaneous warts. The patients' bone marrow (BM) was hypoplastic, with low levels of hematopoietic progenitors, particularly myeloid and B cell precursors. Counts of B cells, monocytes, and DCs were low in the patients' blood, whereas the other blood subsets, including NK cells, were affected only moderately, if at all. The patients had normal counts of Langerhans cells (LCs) and dermal macrophages in the skin but lacked dermal DCs. Thus, FLT3L is required for B </pubmed_abstract><journal>Cell</journal><pubmed_title>FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice.</pubmed_title><pmcid>PMC11149630</pmcid><funding_grant_id>LF-OC-22-000965</funding_grant_id><funding_grant_id>R21 DE028650</funding_grant_id><funding_grant_id>R01 AI143810</funding_grant_id><funding_grant_id>R21 CA271069</funding_grant_id><funding_grant_id>UL1 TR001866</funding_grant_id><funding_grant_id>R21 AI121822</funding_grant_id><funding_grant_id>948959</funding_grant_id><funding_grant_id>R21 CA274265</funding_grant_id><pubmed_authors>Materna M</pubmed_authors><pubmed_authors>Bossuyt X</pubmed_authors><pubmed_authors>Poirier P</pubmed_authors><pubmed_authors>Fouere S</pubmed_authors><pubmed_authors>Claeys KG</pubmed_authors><pubmed_authors>Balogh K</pubmed_authors><pubmed_authors>Schrijvers R</pubmed_authors><pubmed_authors>Perot P</pubmed_authors><pubmed_authors>Pretet JL</pubmed_authors><pubmed_authors>Landegren N</pubmed_authors><pubmed_authors>Parvaneh N</pubmed_authors><pubmed_authors>Nourrisson C</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Langlais D</pubmed_authors><pubmed_authors>Six E</pubmed_authors><pubmed_authors>Esmaeilzadeh H</pubmed_authors><pubmed_authors>Momenilandi M</pubmed_authors><pubmed_authors>Sobrino S</pubmed_authors><pubmed_authors>Fayand A</pubmed_authors><pubmed_authors>Shearer D</pubmed_authors><pubmed_authors>Notarangelo LD</pubmed_authors><pubmed_authors>Abel L</pubmed_authors><pubmed_authors>Casanova JL</pubmed_authors><pubmed_authors>Philippot Q</pubmed_authors><pubmed_authors>Ackermann M</pubmed_authors><pubmed_authors>Ginhoux F</pubmed_authors><pubmed_authors>Yatim A</pubmed_authors><pubmed_authors>Ma CS</pubmed_authors><pubmed_authors>Hu J</pubmed_authors><pubmed_authors>Mulder K</pubmed_authors><pubmed_authors>Youssefian L</pubmed_authors><pubmed_authors>Levy R</pubmed_authors><pubmed_authors>Deswarte C</pubmed_authors><pubmed_authors>Guerin A</pubmed_authors><pubmed_authors>Bustamante J</pubmed_authors><pubmed_authors>Chanal J</pubmed_authors><pubmed_authors>Ogishi M</pubmed_authors><pubmed_authors>Fourgeaud J</pubmed_authors><pubmed_authors>Christensen N</pubmed_authors><pubmed_authors>Cederholm A</pubmed_authors><pubmed_authors>Vahidnezhad H</pubmed_authors><pubmed_authors>Seeleuthner Y</pubmed_authors><pubmed_authors>Bruneau J</pubmed_authors><pubmed_authors>Neehus AL</pubmed_authors><pubmed_authors>Beganovic O</pubmed_authors><pubmed_authors>Meyts I</pubmed_authors><pubmed_authors>Herms F</pubmed_authors><pubmed_authors>Marr N</pubmed_authors><pubmed_authors>Rokni-Zadeh H</pubmed_authors><pubmed_authors>Palterer B</pubmed_authors><pubmed_authors>Jouanguy E</pubmed_authors><pubmed_authors>Waterboer T</pubmed_authors><pubmed_authors>Delmonte OM</pubmed_authors><pubmed_authors>Lachmann N</pubmed_authors><pubmed_authors>Changi-Ashtiani M</pubmed_authors><pubmed_authors>Leclerc-Mercier S</pubmed_authors><pubmed_authors>Bessot B</pubmed_authors><pubmed_authors>Rinchai D</pubmed_authors><pubmed_authors>Wuyts M</pubmed_authors><pubmed_authors>Molina TJ</pubmed_authors><pubmed_authors>Shahrooei M</pubmed_authors><pubmed_authors>Della Mina E</pubmed_authors><pubmed_authors>Tangye SG</pubmed_authors><pubmed_authors>Cremades C</pubmed_authors><pubmed_authors>Boisson-Dupuis S</pubmed_authors><pubmed_authors>Le Floc'h C</pubmed_authors><pubmed_authors>Mancini M</pubmed_authors><pubmed_authors>Denis A</pubmed_authors><pubmed_authors>Khan T</pubmed_authors><pubmed_authors>Beziat V</pubmed_authors><pubmed_authors>Lagresle-Peyrou C</pubmed_authors><pubmed_authors>Brendle S</pubmed_authors><pubmed_authors>Luka M</pubmed_authors></additional><is_claimable>false</is_claimable><name>FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice.</name><description>FMS-related tyrosine kinase 3 ligand (FLT3L), encoded by FLT3LG, is a hematopoietic factor essential for the development of natural killer (NK) cells, B cells, and dendritic cells (DCs) in mice. We describe three humans homozygous for a loss-of-function FLT3LG variant with a history of various recurrent infections, including severe cutaneous warts. The patients' bone marrow (BM) was hypoplastic, with low levels of hematopoietic progenitors, particularly myeloid and B cell precursors. Counts of B cells, monocytes, and DCs were low in the patients' blood, whereas the other blood subsets, including NK cells, were affected only moderately, if at all. The patients had normal counts of Langerhans cells (LCs) and dermal macrophages in the skin but lacked dermal DCs. Thus, FLT3L is required for B </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-04-24T03:19:02.562Z</modification><creation>2026-04-24T03:09:53.858Z</creation></dates><accession>S-EPMC11149630</accession><cross_references><pubmed>38701783</pubmed><doi>10.1016/j.cell.2024.04.009</doi></cross_references></HashMap>